An unusual presentation of metastatic prostate cancer in a 44-year-old man: A case report and review of the literature
Scabies, Cancer And Death Fears: Exclusive Jail Interview With Joe Exotic Reveals Ailing 'Tiger King' Star's Prison Nightmare
ExclusiveOct. 11 2024, Published 6:49 p.M. ET
Joe Exotic isn't living life as a Tiger King like he once was.
RadarOnline.Com can exclusively reveal details about the former Netflix star's nightmare in prison filled with scabies and cancer battles.
Article continues below advertisement
Source: MEGAJoe is serving a 21-year prison sentence after being convicted in a murder-for-hire plot.
Article continues below advertisement
The Tiger King star, 61, is currently serving a 21-year prison sentence after he was convicted in a murder-for-hire plot of Carole Baskin twice, known for being his rival zookeeper.
In the new exclusive interview with RadarOnline.Com, Joe opened up about life in prison and admitted he's "trying to stay alive, but it's hard".
After being diagnosed with prostate cancer in 2021, Joe revealed he was informed it was "in remission," but then received tragic news about a possible lung cancer diagnosis.
He explained that after receiving chest ex-rays, CT scans, and a PET scan over the last year, spots showed up in his left lung in the results.
Article continues below advertisement
Joe was diagnosed with scabies along with 140 other inmates.
Article continues below advertisement
As Joe awaits his biopsy, he claimed the cancer diagnosis has been "advanced" due to "stress" from being in solitary confinement, as well as "the mold and everything else you're living in".
In a press release from October 10, the Fort Worth Federal Medical Center prison announced that Joe was diagnosed with scabies, as well as 140 other inmates.
It also stated 300 inmates are being quarantined and there isn't enough medication for treatment.
MORE ON:
Netflix
DAILY. BREAKING. CELEBRITY NEWS. ALL FREE.
Article continues below advertisement
The Netflix star slammed the system for making him wait 7 months to receive a biopsy to confirm the latest cancer diagnosis.
Joe stated in the interview: "If this is how I have to live for the next 11 years if I don't win my appeal, I pray to God I hope I go home in a body bag soon."
After being asked if he feels as if "he's dying", Joe said: "You wouldn't believe how many people die in here before they get care."
If the biopsy confirms he has cancer, Joe stated that he will be "declining" treatment.
Article continues below advertisement
Source: netflixIf the biopsy confirms he has cancer, Joe stated that he will be "declining" treatment.
Article continues below advertisement
The star said he's "ashamed" of the Federal Government adding: "Everybody lies. President Biden and Vice President Harris stood on that stage during Covid at that drive-in when they were campaigning, promised prison justice reforms and they have done nothing. Except let more people die.
"From the lack of proper food, the lack of medical care. They have done nothing. And I am ashamed to even say I am an American."
Article continues below advertisement
Source: NETFLIXJoseph Maldonado-Passage, better known as Joe Exotic, is fighting cancer while in prison.
Aga Khan University Hospital Conducts First Prostate PET-CT Scan
Daniel Oguna, a PET CT technologist prepares a patient for a scan procedure at Aga Khan University Hospital, Nairobi. [Photo: Standard]
The latest and most advanced scan for evaluation of patients with prostate cancer is now available at the Aga Khan University Hospital, Nairobi.
The Prostate-Specific Membrane Antigen (PSMA) PET CT scan has been available for only a few years and in the most advanced medical centres in the world.
In a statement, the hospital said the scan allows for better treatment options of the disease while still in an early stage.
In view of its higher sensitivity, this scan can identify sites of early prostate cancer spread before they are picked up by conventional imaging modalities.
"This is bound to have a major impact on the successful outcomes of the treatment for those with prostate cancer," a statement from the hospital read in part.
Prostate Cancer PET-CT scan can detect the location and extent of cancer that has recurred after initial treatment and spread to other parts of the body. Prostate PET-CT scans can also detect cancer earlier than either CT scans alone or MRI scans.
"Following advancement in our PET CT scan technology and growth in the expertise of our radiology and laboratory departments, AKUH, N is now able to produce the radioactive substance required for this scan as well as conduct the test," the statement further stated.
Prostate cancer causes at least 1,663 deaths every year out of 2,864 cases recorded.
According to a report tabled in Parliament by National Cancer Institute of Kenya (NCI-K), Globocan 2018 estimates show that there are 47,887 new cases of cancer daily and 32,987 deaths annually.
Compared to the presently established methods of imaging prostate cancer such as MRI and bone scan, PSMA PET CT scan has a higher sensitivity for identification of sites of prostate cancer spread, be it in the bones or in any other organs such as lymph nodes, liver and lungs.
"It can be used for this purpose at the initial diagnosis of the disease, during follow-up and when disease recurrence is suspected," the hospital said.
It added: "The capacity to conduct this test adds to the expertise of our PET CT Scan and Cyclotron, a technology we acquired in 2018 at a cost of Sh600 million."
After the initial diagnosis of prostate cancer, patients undergo treatment such as surgery, cryotherapy or radiation. In some cases, cancer may recur. Following treatment, patients are monitored with periodic PSA blood tests.
Stay informed. Subscribe to our newsletter
Sarasota Memorial Research Institute Participates In Groundbreaking Prostate Cancer Imaging Study
(MENAFN- PR Newswire) SARASOTA, Fla., Oct. 21, 2024 /PRNewswire/ -- Prostate cancer is the most common non-skin cancer in men in the US, and the 4th most common tumor diagnosed worldwide. As part of its commitment to improving the diagnosis and staging of this disease, Sarasota Memorial Research Institute is proud to announce its participation in the Solar-Stage study sponsored by Curium. This clinical trial aims to evaluate a new investigational diagnostic product, Copper Cu 64PSMA I&T Injection, for its ability to provide detailed images of prostate cancer tumors using positron emission tomography (PET) and computed tomography (CT) scans. The Copper Cu 64 PSMA I&T injection is under development as a radioactive PET imaging agent that specifically targets the prostate specific membrane antigens that are expressed on metastatic prostate cancer cells.
Continue ReadingRobert I. Carey, MD PhD FACS, principal investigator of the prostate cancer study at Sarasota Memorial.The study seeks to determine if Copper Cu 64 PSMA I&T Injection can safely and effectively be used to accurately stage prostate cancer by taking precise pictures of tumors in the body. Accurate staging is critical in guiding treatment decisions and improving patient outcomes. The safety and effectiveness of copper Cu 64 PSMA I&T have not been established by the United States Food and Drug Administration.
Participants in the study will undergo a series of evaluations. The process includes a screening visit to review medical history and obtain consent, followed by an imaging day where the injection will be administered, and PET/CT scans will be conducted to capture detailed images of the prostate cancer tumors. Participants will also receive follow-up care to monitor for any side effects and ensure their well-being. If surgery is part of their medical care, information from the procedure may be used in the research study.
"In terms of cancer specific survival, the higher the risk of prostate cancer at the time of diagnosis, the greater the benefit to have a robotic prostatectomy with an extended pelvic lymph node dissection as the first treatment for prostate cancer," said Robert I. Carey, MD PhD FACS, Principal Investigator of this prostate cancer study. "My hope is that the Curium 64 Solar Stage Research Study will help patients by clearly and accurately outlining the extent of their disease prior to surgery. It may allow for specific targeting and removal of lymph nodes distant to the prostate that might otherwise not be treated in other prostate cancer therapies. Patients could benefit from such treatments and may be spared future toxic therapies. We are very fortunate to have the study available in Sarasota for our patients."
Inclusion Criteria:
Exclusion Criteria:
Sarasota Memorial Research Institute remains committed to advancing medical research and improving patient care through innovative clinical trials. The Curium 64 Solar Stage Research Study represents a promising opportunity to explore new diagnostic tools that could significantly impact the future of prostate cancer treatment.
For more information about the trial and enrollment criteria, call Sarasota Memorial's Research Institute at (941) 917-2225 or visit the FDA clinical trial webpage at:
About the Sarasota Memorial Research Institute Sarasota Memorial Research Institute (SMRI) provides advanced research and a highly qualified staff to advance the latest treatment options for patients in the Suncoast community. Located on Sarasota Memorial Health Care System's Sarasota campus, the Research Institute provides the knowledge, expertise, and infrastructure essential to evaluate and manage innovative drug, device, registry, and biospecimen clinical trials. SMRI offers research trials across a wide spectrum of disease processes, including cardiology, infectious disease, gastroenterology, neurology, oncology, pulmonology, urology, vascular, and more. For more information about clinical studies or participating in clinical trials, contact the Sarasota Memorial Research Institute at (941) 917-2225 or you can contact the office of Dr. Carey at (941)-917-5400.
SOURCE Sarasota Memorial Health Care System
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+Newsrooms &Influencers 9k+Digital MediaOutlets 270k+JournalistsOpted In GET STARTEDMENAFN21102024003732001241ID1108803032
Legal Disclaimer:MENAFN provides the information "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
Comments
Post a Comment